- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Halozyme Therapeutics Inc(HALO)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for HALO
11/13/2026: HALO (3-star) is a SELL. SELL for 3 days. Simulated Profits (48.11%). Updated daily EoD!
Halozyme Therapeutics is a specialized biotechnology company known for its proprietary ENHANZE drug delivery platform, which converts intravenous treatments into convenient subcutaneous injections. The company's main business strength lies in its asset-light, high-margin royalty model, fueled by stellar sales uptake from blockbuster partner products like DARZALEX SC and VYVGART Hytrulo. Its primary growth story centers on expanding partner pipelines and integrating next-generation device technologies like Hypercon. However, key risks include customer concentration on a few partner drugs and ongoing intellectual property litigation. The stock suits growth-oriented investors willing to monitor partner execution, regulatory milestones, and patent defense developments.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Halozyme offers robust double-digit revenue and earnings expansion driven by expanding global royalty streams from partner blockbusters. |
| Momentum investor | Strong fit while signal remains positive | The stock frequently exhibits strong upward price momentum supported by raised financial guidance and strong quarterly outperformance. |
| Value investor | Mixed fit | While trading at attractive price-to-earnings metrics relative to its growth rate, it operates in biotech where sentiment can shift quickly. |
| Dividend investor | Weak fit | The company does not pay a dividend, favoring capital reinvestment and share buybacks instead. |
| Low-risk investor | Medium | Although it benefits from high profit margins and cash flows, it remains subject to biotechnology sector volatility and partner concentration risks. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | Biotechnology stocks experience periodic price swings based on macro sector sentiment, clinical updates, and litigation outcomes. |
| Valuation risk | Medium | Market expectations are high given strong growth guidance, leaving little room for operational missteps. |
| Competition risk (partner platform and alternative delivery competition) | Medium | Alternative formulation technologies or rival delivery systems could threaten long-term partner retention. |
| Business quality | Strong | Halozyme's high-margin royalty model and asset-light structure reflect exceptional underlying franchise quality. |
| Dividend income | Low / none | Income-focused investors will find no dividend support as capital is allocated to growth and buybacks. |
| Execution risk | Medium | Successful integration of recent acquisitions like Elektrofi and execution on device programs are vital to maintaining growth. |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 11.43B USD | Price to earnings Ratio 25.07 | 1Y Target Price 119.89 |
Price to earnings Ratio 25.07 | 1Y Target Price 119.89 | ||
Volume (30-day avg) 2.3M shares | Beta 0.9 | 52 Weeks Range 61.23 - 134.00 | Updated Date 11/15/2026 |
52 Weeks Range 61.23 - 134.00 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 4 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.

Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit -7.03% | Avg. Invested days 42 | Today’s Advisory SELL |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Royalty Revenues | Royalty payments collected from commercialized partner products utilizing the ENHANZE technology platform (e.g., DARZALEX SC, Phesgo, VYVGART Hytrulo). | This is the core profit engine, acting like a tollbooth on major global biologic blockbusters. |
| Product Sales & API | Sales of bulk rHuPH20 enzyme to collaboration partners, specialized proprietary products, and legacy device offerings. | Provides reliable recurring manufacturing and material sales tied directly to partner commercial supply chains. |
| Milestone and Upfront Revenues | Contractual milestone payments and licensing fees received upon achieving development, regulatory, or commercial hurdles with partners. | Lumpy cash inflows that boost earnings when partner drugs advance successfully through clinical pipelines. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-11-05 | When After Market | Estimate 2.17 | Actual 2.27 |
Profitability
Profit Margin 26.93% | Operating Margin (TTM) 56.68% |
Management Effectiveness
Return on Assets (TTM) 22.42% | Return on Equity (TTM) 216.38% |
Valuation
Trailing PE 25.07 | Forward PE 10.56 | Enterprise Value 13.61B | Price to Sales(TTM) 6.34 |
Enterprise Value 13.61B | Price to Sales(TTM) 6.34 | ||
Enterprise Value to Revenue 7.55 | Enterprise Value to EBITDA 16.89 | Shares Outstanding 114.01M | Shares Floating 112.70M |
Shares Outstanding 114.01M | Shares Floating 112.70M | ||
Percent Insiders 2.45 | Percent Institutions 113.19 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

